Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Sato Yakuhin Kogyo Co., Ltd.

    Client Virtual Booth

    SATO YAKUHIN KOGYO CO., LTD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Sato Yakuhin Kogyo Co., Ltd
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    9-2, Kannonji-Cho, Kashihara City Nara Prefecture 634-8567
    Telephone
    Telephone
    0744-28-0021
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.sato-yakuhin.co.jp/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

    Details:

    The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.


    Lead Product(s): Roflumilast

    Therapeutic Area: Dermatology Product Name: Zoryve

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Arcutis Biotherapeutics

    Deal Size: $40.0 million Upfront Cash: $25.0 million

    Deal Type: Collaboration February 28, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan

    Details:

    Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.


    Lead Product(s): Oxymetazoline Hydrochloride

    Therapeutic Area: Dermatology Product Name: Rhofade

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: EPI Health

    Deal Size: $7.5 million Upfront Cash: $5.0 million

    Deal Type: Licensing Agreement December 21, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search